Autolus Therapeutics

Autolus Therapeutics is a CAR T cell therapy company spun out of University College London that markets AUCATZYL and engineers programmed T cell therapies. The company also maintains a pipeline of product candidates in development for hematological malignancies, solid tumors, and autoimmune diseases.

Obe-cel is an autologous CD19 CAR T cell therapy whose proprietary CAR has a fast off-rate mimicking physiological T-cell receptor interactions. AUCATZYL is a treatment option for physicians treating adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Autolus uses a broad suite of proprietary and modular T cell programming technologies to engineer precisely targeted and controlled T cell therapies.